France Antibody Drug Conjugates Market Size & Outlook

The antibody drug conjugates market in France is expected to reach a projected revenue of US$ 664.5 million by 2030. A compound annual growth rate of 16.5% is expected of France antibody drug conjugates market from 2022 to 2030.
Revenue, 2021 (US$M)
$167.6
Forecast, 2030 (US$M)
$811.8
CAGR, 2022 - 2030
19.2%
Report Coverage
France

France antibody drug conjugates market highlights

  • The France antibody drug conjugates market generated a revenue of USD 167.6 million in 2021 and is expected to reach USD 811.8 million by 2030.
  • The France market is expected to grow at a CAGR of 19.2% from 2022 to 2030.
  • In terms of segment, breast cancer was the largest revenue generating application in 2021.
  • Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.


Antibody drug conjugates market data book summary

Market revenue in 2021USD 167.6 million
Market revenue in 2030USD 811.8 million
Growth rate19.2% (CAGR from 2021 to 2030)
Largest segmentBreast cancer
Fastest growing segmentBlood Cancer
Historical data2018 - 2020
Base year2021
Forecast period2022 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBlood Cancer, Breast Cancer
Key market players worldwidePfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA


Other key industry trends

  • In terms of revenue, France accounted for 2.9% of the global antibody drug conjugates market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
  • Italy is the fastest growing regional market in Europe and is projected to reach USD 758.8 million by 2030.

Breast cancer was the largest segment with a revenue share of 67.9% in 2021. Horizon Databook has segmented the France antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.


As per the International Agency for Research on Cancer, France with 467,995 new cases in 2020 was among the top 10 countries worldwide in terms of cancer incidence. The French Universal Health Coverage is mandatory for all citizens and provides full coverage for Long Tern Diseases (LTDs) such as cancer, with ADC drugs such as Roche’s Kadcyla already on the reimbursement list.

French pharmaceutical companies are actively investing in the development of ADC drugs. For instance, Sanofi’s SAR408701 is in phases 3 and 2 of clinical trials for non-small cell lung cancer & solid tumors, respectively.

High prevalence of cancer in France, excellent health care support for patients with LTDs, and ongoing R&D efforts from local pharmaceutical companies to develop new drugs are expected to propel the demand for ADC drugs market over the forecast period.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antibody Drug Conjugates Market Companies

Name Profile # Employees HQ Website

France antibody drug conjugates market size, by application, 2018-2030 (US$M)

France Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)

France antibody drug conjugates market size, by application, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more